Literature DB >> 7975147

Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines.

S Chandrasekaran1, L Kennett, P C Yeap, N Muniandy, B Rani, T K Mukkur.   

Abstract

Two of the three buffaloes immunized with a non-adjuvanted broth bacterin were found to be protected against experimental challenge at 6 weeks but not at 3 months post-challenge. Similarly all buffaloes (4/4) immunized with alum-precipitated vaccine were protected at 6 months but only 1 of the 2 vaccinated animals were protected at 12 months post-immunization. On the other hand, buffaloes immunized with an oil adjuvant and a double emulsion vaccine were completely protected at 12 months post-immunization. Statistically significant differences between immunized versus non-immune animals became evident at 3 months post-immunization, although analysis of cumulative antibody titres of pre-challenge sera of vaccinated buffaloes surviving versus those succumbing to experimental challenge revealed significant by higher antibody titres in the former as compared to the latter group. These results suggested that there was a relationship between ELISA antibody titres and active protection in buffaloes. There also appeared to be a relationship between cutaneous delayed-type hypersensitivity and active protection in buffaloes. Preliminary analysis of the antibody isotype distribution in the pre-challenge sera of 2 buffaloes vaccinated with the oil adjuvant vaccine revealed predominance of IgG1 and IgG2 subclasses whose role in protection against haemorrhagic septicaemia was not eludicated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7975147     DOI: 10.1016/0378-1135(94)90102-3

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Safety and protective efficacy of intramuscular vaccination with a live aroA derivative of Pasteurella multocida B:2 against experimental hemorrhagic septicemia in calves.

Authors:  Mark P Dagleish; J Christopher Hodgson; Saeed Ataei; Anna Finucane; Jeanie Finlayson; Jill Sales; Roger Parton; John G Coote
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

2.  Efficacy of vaccination of calves against hemorrhagic septicemia with a live aroA derivative of Pasteurella multocida B:2 by two different routes of administration.

Authors:  J Christopher Hodgson; Anna Finucane; Mark P Dagleish; Saeed Ataei; Roger Parton; John G Coote
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

3.  Protective effect following intranasal exposure of goats to live Pasteurella multocida B:2.

Authors:  M Zamri-Saad; Z A Ernie; M Y Sabri
Journal:  Trop Anim Health Prod       Date:  2006 Oct-Nov       Impact factor: 1.559

4.  Efficacy of an inactivated recombinant vaccine encoding a fimbrial protein of Pasteurella multocida B:2 against hemorrhagic septicemia in goats.

Authors:  Ina-Salwany Mohd Yasin; Sabri Mohd Yusoff; Zamri-Saad Mohd; Effendy Abd Wahid Mohd
Journal:  Trop Anim Health Prod       Date:  2010-08-10       Impact factor: 1.559

5.  Protective immunity conferred by attenuated aroA derivatives of Pasteurella multocida B:2 strains in a mouse model of hemorrhagic septicemia.

Authors:  Mohammad Tabatabaei; Zhiqi Liu; Anna Finucane; Roger Parton; John Coote
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

6.  Effect of alum co-adjuvantation of oil adjuvant vaccine on emulsion stability and immune responses against haemorhagic septicaemia in mice.

Authors:  Sujeet Kumar; Vinod Kumar Chaturvedi; Bablu Kumar; Pankaj Kumar; Sudha Rani Somarajan; Anil Kumar Mishra; Bhaskar Sharma
Journal:  Iran J Microbiol       Date:  2015-04

7.  Intranasal immunization with a recombinant outer membrane protein H based Haemorrhagic septicemia vaccine in dairy calves.

Authors:  Korkiat Muangthai; Pallop Tankaew; Thanya Varinrak; Ratchanee Uthi; Suvichai Rojanasthien; Takuo Sawada; Nattawooti Sthitmatee
Journal:  J Vet Med Sci       Date:  2017-11-06       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.